Orforglipron (Foundayo) is a GLP-1 pill, a small molecule approved by the FDA in 2026 for weight management. Tirzepatide (Mounjaro, Zepbound) is an injected peptide that acts on the GIP and GLP-1 receptors, approved in the US and EU for type 2 diabetes and weight management. This page compares their study results.
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Tirzepatide | |
|---|---|---|
| Identity | ||
| Kind | Small molecule | Synthetic analog |
| Area | Weight and metabolic | Weight and metabolic |
| Evidence | ||
| Amount of evidence | 340 | 2,165 |
| Evidence level | Has results from studies in people | Has results from studies in people |
| Safety | ||
| Safety results | 121 (119 in people) | 462 (462 in people) |
| Status | ||
| Approval | ||
| Sport (WADA) | ||
| Registered trials | 53 · 20 active1 more mentions it but does not test it | 254 · 162 active47 more mention it but do not test it |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Foundayo says: “With a reduced-calorie diet and increased physical activity: reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition” No central EU authorisation (EMA).
The FDA label for Mounjaro says: “Adjunct to diet and exercise for glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Orforglipron | Tirzepatide |
|---|---|---|
| Body weightMetabolic and weight | 66633 | 521501182 |
| Glycemic controlMetabolic and weight | 54513 | 36435581 |
| Adverse eventsWhole body | 545211 | 213213 |
| Gastrointestinal adverse eventsGastrointestinal | 4646 | 179179 |
| Cardiovascular eventsCardiovascular | 211 | 1551523 |
| LipidsMetabolic and weight | 13121 | 79763 |
| MortalityWhole body | 88 | 635724 |
| Liver fat and liver functionLiver | 99 | 5353 |
| Blood pressureCardiovascular | 66 | 5151 |
| Heart functionCardiovascular | 66 | 49427 |
| PharmacokineticsPharmacology | 383332 | 16133 |
| Inflammation markersImmune and inflammation | 413 | 41347 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Orforglipron | Tirzepatide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −8.6 to −12.6% Weight change Placebo: −2% Dose studied: 12, 24, 36, or 45 mg once daily26 weeksn = 2722023 | −20.9% Mean percentage weight reduction at week 72 · Shown as a change. The study reports a mean percentage weight reduction at week 72 of this size. · tirzepatide 15 mg Placebo: −3.1% Dose studied: 5 mg, 10 mg or 15 mg once weekly72 weeks, including a 20-week dose-escalation periodn = 2,5392022 |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | −1.08% Estimated treatment difference in HbA1c vs placebo Dose studied: 12 mg once daily40 weeksn not reported2026 | −0.4% HbA1c mean difference Dose studied: 2.5 mg for 4 weeks, 5.0 mg for 8 weeks12 weeksn not reported2026 |
| Adverse eventsMetabolic and weightCompared as: value in the arm that got the peptide, in % | 81.5 to 92.5% 95% confidence interval for TEAE percentage · orforglipron 36 mg Dose studied: 36 mg once daily52 weeksn = 2692026 | 6.3% discontinuation due to adverse events Placebo: 1.4% Dose studied: up to 15 mg once weeklyat least 52 weeksn = 7312025 |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 3 to 11.3% Confidence interval (level not stated) for gastrointestinal discontinuation percentage · orforglipron 12 mg Dose studied: 12 mg once daily52 weeksn = 1352026 | 1 to 10.5% Discontinuation due to GI AEs n not reported2025 |
−8.6 to −12.6%
Weight change
Placebo: −2%
Dose studied: 12, 24, 36, or 45 mg once daily26 weeksn = 2722023
−20.9%
Mean percentage weight reduction at week 72 · Shown as a change. The study reports a mean percentage weight reduction at week 72 of this size. · tirzepatide 15 mg
Placebo: −3.1%
Dose studied: 5 mg, 10 mg or 15 mg once weekly72 weeks, including a 20-week dose-escalation periodn = 2,5392022
−1.08%
Estimated treatment difference in HbA1c vs placebo
Dose studied: 12 mg once daily40 weeksn not reported2026
−0.4%
HbA1c mean difference
Dose studied: 2.5 mg for 4 weeks, 5.0 mg for 8 weeks12 weeksn not reported2026
81.5 to 92.5%
95% confidence interval for TEAE percentage · orforglipron 36 mg
Dose studied: 36 mg once daily52 weeksn = 2692026
6.3%
discontinuation due to adverse events
Placebo: 1.4%
Dose studied: up to 15 mg once weeklyat least 52 weeksn = 7312025
3 to 11.3%
Confidence interval (level not stated) for gastrointestinal discontinuation percentage · orforglipron 12 mg
Dose studied: 12 mg once daily52 weeksn = 1352026
1 to 10.5%
Discontinuation due to GI AEs
n not reported2025
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Orforglipron | Tirzepatide |
|---|---|---|
| Cardiovascular eventsCardiovascularCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 23.7% event rate Dose studied: up to 15 mg weeklymedian 46.9 monthsn = 13,1652026 |
| Heart functionCardiovascularCompared as: difference from placebo, in points | No comparable result 4 randomized-trial results measure it in another way or another unit. | 6.9 points between-group difference Dose studied: up to 15 mg once weeklyat least 52 weeksn = 7312025 |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in days | No comparable result 14 randomized-trial results measure it in another way or another unit. | ≈ 5 days Half-life Dose studied: 5, 10 or 15 mg8 weeksn = 482022 |
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | No comparable result 3 randomized-trial results measure it in another way or another unit. | −6.8 mm Hg Net systolic blood pressure reduction · Shown as a change. The study reports a net systolic blood pressure reduction of this size. 72 weeksn not reported2024 |
| Cardiometabolic risk factorsMetabolic and weightCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | −4.6% Mean percent change in ASCVD risk (ACC/AHA) · tirzepatide 5 mg Placebo: 57.9% Dose studied: 5 mg176 weeksn not reported2025 |
| LipidsMetabolic and weightCompared as: value in the arm that got the peptide, in % | No comparable result 7 randomized-trial results measure it in another way or another unit. | ≤ 22.9% Variability in triglyceride change explained by apoC-III change Dose studied: 1, 5, 10 or 15 mg once weekly26 weeksn not reported2020 |
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in kcal | No randomized trial result 3 results from other study designs. | −524.6 kcal Estimated treatment difference n not reported2025 |
| MortalityCardiovascularCompared as: value in the arm that got the peptide, in % | 1.4% Deaths Dose studied: Maximum tolerated dose up to 36 mg capsule, equivalent to 17.2 mg tablet, once dailyMedian follow-up of 2 yearsn = 2,7262026 | No comparable result 7 randomized-trial results measure it in another way or another unit. |
No comparable result
1 randomized-trial result measure it in another way or another unit.
23.7%
event rate
Dose studied: up to 15 mg weeklymedian 46.9 monthsn = 13,1652026
No comparable result
4 randomized-trial results measure it in another way or another unit.
6.9 points
between-group difference
Dose studied: up to 15 mg once weeklyat least 52 weeksn = 7312025
No comparable result
14 randomized-trial results measure it in another way or another unit.
≈ 5 days
Half-life
Dose studied: 5, 10 or 15 mg8 weeksn = 482022
No comparable result
3 randomized-trial results measure it in another way or another unit.
−6.8 mm Hg
Net systolic blood pressure reduction · Shown as a change. The study reports a net systolic blood pressure reduction of this size.
72 weeksn not reported2024
No comparable result
1 randomized-trial result measure it in another way or another unit.
−4.6%
Mean percent change in ASCVD risk (ACC/AHA) · tirzepatide 5 mg
Placebo: 57.9%
Dose studied: 5 mg176 weeksn not reported2025
No comparable result
7 randomized-trial results measure it in another way or another unit.
≤ 22.9%
Variability in triglyceride change explained by apoC-III change
Dose studied: 1, 5, 10 or 15 mg once weekly26 weeksn not reported2020
No randomized trial result
3 results from other study designs.
−524.6 kcal
Estimated treatment difference
n not reported2025
1.4%
Deaths
Dose studied: Maximum tolerated dose up to 36 mg capsule, equivalent to 17.2 mg tablet, once dailyMedian follow-up of 2 yearsn = 2,7262026
No comparable result
7 randomized-trial results measure it in another way or another unit.
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Tirzepatide differs from Gastric inhibitory polypeptide (GIP) at 11 positions and in 1 end segment.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 53 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company3,127 participants5 Jun 2023 to est. Oct 2027
Obesity · Overweight · Overweight or Obesity
Eli Lilly and Company1,698 participants22 Sept 2023 to 22 Aug 2025
Type 2 Diabetes
Eli Lilly and Company1,613 participants5 Jun 2023 to 8 Aug 2025
Obesity · Overweight · Type 2 Diabetes
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 254 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company13,299 participants29 May 2020 to 12 Jun 2025
Type 2 Diabetes Mellitus
Eli Lilly and Company2,539 participants4 Dec 2019 to 6 Jul 2024
Overweight · Obesity
Eli Lilly and Company2,002 participants20 Nov 2018 to 22 Apr 2021
Type 2 Diabetes Mellitus
47 more mention it but do not test it. They only measure it or name it in their text.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated